Myostatin is one of the most powerful negative regulators of skeletal muscle growth in the human body. Secreted by muscle cells, it acts as a biological brake, preventing muscles from growing too large. The K153R polymorphism (Lys153Arg) sits within the mature active peptide¹¹ mature active peptide
the bioactive portion of myostatin after proteolytic processing of the myostatin protein, where it can influence both how the protein is processed and how effectively it binds to its receptor, ActRIIB²² ActRIIB
activin type II receptor B, the primary receptor through which myostatin signals.

The rare R (arginine) variant appears to reduce myostatin's inhibitory effect, effectively loosening the brake on muscle growth. This has made it a variant of intense interest in sports genetics research.

The Mechanism

Myostatin is synthesized as a latent precursor protein that undergoes proteolytic processing to become the mature, bioactive peptide. The K153R substitution occurs at amino acid position 153 in this mature region. The replacement of lysine (K) with arginine (R) — both positively charged amino acids but with different side chain properties — may affect either the proteolytic processing of myostatin or its binding affinity to the ActRIIB receptor³³ may affect either the proteolytic processing of myostatin or its binding affinity to the ActRIIB receptor
Lys and Arg have similar charge but different side chain structures that could alter protein-protein interactions.

When myostatin binds to ActRIIB on muscle cells, it activates intracellular signaling cascades that inhibit both myoblast (muscle precursor cell) proliferation and differentiation, ultimately limiting muscle mass accumulation. Any variant that reduces this signaling — whether through altered processing, reduced receptor binding, or decreased protein stability — would be expected to permit greater muscle growth in response to mechanical loading (resistance training) or muscle-building stimuli⁴⁴ muscle-building stimuli
anabolic signals like IGF-1, testosterone, and mechanical tension from exercise.

The Evidence

The most comprehensive examination of this variant comes from a 2022 meta-analysis⁵⁵ 2022 meta-analysis
Kruszewski & Aksenov. Association of Myostatin Gene Polymorphisms with Strength and Muscle Mass in Athletes. Genes, 2022 that analyzed 71 research articles on MSTN polymorphisms. The meta-analysis included 4 studies with 773 athletes and 357 controls across 5 ethnic groups. The key finding: strength-oriented athletes had a significantly higher frequency of the R variant compared to controls (OR = 2.02, p = 0.05). Among athletes, those carrying the R variant showed greater muscle strength and mass gains from power-oriented training compared to KK carriers.

However, the picture is more nuanced than "R = better muscles." A 2011 study of 281 young non-athletic men⁶⁶ 2011 study of 281 young non-athletic men
Santiago et al. The K153R Polymorphism in the Myostatin Gene and Muscle Power Phenotypes in Young, Non-Athletic Men. PLoS One, 2011 found that R allele carriers actually performed worse on vertical jump tests, showing decreased peak power production during explosive movements. This suggests the R variant may offer advantages specifically in the context of chronic resistance training adaptation, but not necessarily in baseline explosive power in untrained individuals.

The strongest evidence for functional impact comes from a training intervention study in Han Chinese men⁷⁷ training intervention study in Han Chinese men
Wang et al. The A55T and K153R polymorphisms of MSTN gene are associated with strength training-induced muscle hypertrophy. J Sports Sci, 2014. Among 94 previously untrained men who completed an 8-week strength training program, those with the KR genotype showed significantly greater muscle thickness gains: +0.30 cm in biceps and +0.42 cm in quadriceps compared to KK genotype carriers (p < 0.01 for both). This represents approximately 40-50% greater hypertrophy response from identical training stimulus.

The evidence level is moderate rather than strong due to the rarity of the R allele (3-4% in Europeans, making RR homozygotes extraordinarily rare at <1%) and some contradictory findings across studies. The meta-analysis showed moderate heterogeneity (I² = 33%), suggesting population-specific effects or gene-environment interactions.

Practical Actions

For KR or RR carriers, the variant suggests enhanced potential for muscle hypertrophy in response to progressive resistance training. This doesn't mean you'll automatically build more muscle — training, nutrition, and recovery remain primary determinants — but it suggests your ceiling for muscle growth may be higher than average when these factors are optimized.

Optimal training for leveraging this genetic advantage involves progressive overload with compound movements (squats, deadlifts, bench press, overhead press, rows), training each muscle group 2-3 times per week with sufficient volume (15-25 sets per muscle per week), and ensuring adequate protein intake (1.6-2.2 g/kg body weight daily). Recovery between sessions is crucial — the variant affects adaptation capacity, but adaptation still requires rest.

For AA (KK) carriers, this is the normal, wild-type genotype present in ~94% of Europeans. Myostatin regulation is functioning as designed. You have standard muscle growth potential, which is still substantial when training and nutrition are optimized. The absence of the R variant doesn't limit you to below-average muscle growth — it simply means you lack a rare genetic advantage.

Interestingly, a 2020 Mexican study⁸⁸ 2020 Mexican study
Castro-Rodríguez et al. The Myostatin rs1805086 variant is associated with obesity in Mexican adults. Gene, 2020 found the R allele associated with obesity independently of metabolic risk factors, suggesting that reduced myostatin activity may have trade-offs beyond the muscle compartment. This reinforces that no variant is universally "good" — context matters.

Interactions

The K153R variant shows documented interaction with another MSTN polymorphism, A55T (rs1805065). The same Han Chinese training study found that individuals carrying variant alleles of both polymorphisms showed the greatest training-induced muscle hypertrophy. The A55T variant is located in exon 1 of myostatin, also in the mature peptide region. These two variants may have additive or synergistic effects on reducing myostatin's inhibitory function.

There is theoretical but less well-documented interaction with ACTN3 R577X (rs1815739), the "sprinter gene" that determines fast-twitch muscle fiber composition. Since myostatin preferentially affects fast-twitch (type II) muscle fibers, and ACTN3 determines the presence of alpha-actinin-3 protein exclusively in type II fibers, carriers of both the MSTN R allele and the ACTN3 RR genotype might show enhanced power and strength potential. However, studies specifically examining this interaction have shown null results for combined effects on longevity⁹⁹ null results for combined effects on longevity
Hirose et al. Muscle-Related Polymorphisms (MSTN rs1805086 and ACTN3 rs1815739) Are Not Associated with Exceptional Longevity. PLoS One, 2016, suggesting the interaction may be context-dependent.

Nutrition-gene interaction is worth considering: adequate protein intake becomes even more critical for KR/RR carriers to realize the hypertrophic potential. The enhanced capacity for muscle protein synthesis means substrate availability (dietary protein) becomes rate-limiting faster than in TT carriers.

Inside every cell of your body ticks a molecular clock, cycling with almost perfect 24-hour precision. The CRY1 protein is one of its master regulators — a transcriptional brake that keeps the CLOCK:BMAL1 activator complex from running perpetually. The CRY1Δ11 variant (c.1657+3A>C on the coding strand, NC_000012.12:g.106992962T>G¹¹ NC_000012.12:g.106992962T>G
genomic HGVS notation, GRCh38 plus strand) disrupts a splice site at the boundary of intron 11, causing the entire exon 11 to be skipped during mRNA processing. The result is a CRY1 protein missing 24 amino acids from its C-terminal tail — and it is more powerful, not less. This gain-of-function makes the mutant CRY1 cling more tightly to CLOCK and BMAL1, prolonging transcriptional inhibition and stretching the molecular clock period from 24 hours to roughly 24.5 hours. Half an hour per cycle compounds: carriers' sleep timing drifts 2–2.5 hours later than their circadian phase actually warrants²² carriers' sleep timing drifts 2–2.5 hours later than their circadian phase actually warrants
Patke et al. Cell 2017, producing the signature symptom of Delayed Sleep Phase Disorder.

The Mechanism

The 5' splice site of intron 11 contains the sequence the spliceosome uses to remove intron 11 and join exon 11 to exon 12. The c.1657+3A>C transversion weakens this recognition sequence enough that the spliceosome skips exon 11 entirely. The resulting mRNA encodes a CRY1 protein with an in-frame 24-amino acid deletion in the C-terminal tail domain³³ tail domain
The C-terminal tail modulates CRY1's interaction surface with CLOCK and BMAL1. Counterintuitively, this deletion enhances rather than impairs CRY1's function. The mutant protein localizes to the nucleus more readily than wild-type CRY1, occupies CLOCK:BMAL1 binding sites on chromatin for longer, and suppresses transcription of circadian target genes — including Per1, Per2, and Dbp — more persistently. Chromatin immunoprecipitation studies showed the mutant CRY1 displaced CLOCK and BMAL1 from their target gene promoters⁴⁴ Chromatin immunoprecipitation studies showed the mutant CRY1 displaced CLOCK and BMAL1 from their target gene promoters
Consistent with a dominant gain-of-function mechanism. The net effect is a circadian period that runs slow, anchoring the person's internal clock later and later relative to the external light-dark cycle.

The Evidence

The founding study by Patke et al. in Cell (2017)⁵⁵ Patke et al. in Cell (2017)
PMID 28388406 identified CRY1Δ11 in affected members of seven unrelated Turkish families with familial DSPD. In a validation cohort of 70 subjects from six families (8 homozygous carriers, 31 heterozygous carriers, 31 non-carriers), the variant segregated with DSPD with a Fisher's exact P < 0.0001 and an odds ratio of 1,928 — an effect size rarely seen in common-disease genetics. In temporal isolation experiments, the proband's free-running circadian period measured 24.52 hours. In vitro, mouse embryonic fibroblasts expressing the mutant CRY1 showed a period lengthened by approximately 30 minutes relative to cells expressing wild-type CRY1. The variant frequency in the gnomAD database is approximately 0.4% globally, rising to 0.65% in non-Finnish Europeans and ~3% in Ashkenazi Jewish populations, consistent with Patke et al.'s estimate that roughly 1 in 75 people of certain ancestries carry this allele⁶⁶ Patke et al.'s estimate that roughly 1 in 75 people of certain ancestries carry this allele
Making it one of the most common single-gene causes of a sleep disorder ever identified.

A follow-up observational study by Smieszek et al. (2021)⁷⁷ observational study by Smieszek et al. (2021)
Sci Rep, PMID 34635699 enrolled 67 participants (33 CRY1Δ11 carriers, 34 wild-type controls) from Turkish families and confirmed that carriers had significantly later wake times, sleep midpoints, and longer sleep-onset latency. Remarkably, the circadian delay extended to metabolic outputs: bowel movement timing was approximately 91 minutes later in carriers (p = 0.002), demonstrating that the lengthened period affects the entire peripheral clock network, not just the central sleep-wake system.

A 2020 study by Onat et al. in JCI⁸⁸ Onat et al. in JCI
PMID 32538895 extended the phenotype. Among 96 individuals from 12 Turkish families with combined ADHD and DSPD, CRY1Δ11 was present in 13% of affected individuals versus 0% of controls (OR 281, P = 1.99 × 10⁻²¹). A phenome-wide association study in 9,438 unrelated European adults found the variant associated with major depressive disorder, insomnia, anxiety, and nicotine dependence. Of 48 CRY1Δ11 carriers with available psychiatric records, 46 (96%) displayed ADHD symptoms, and 64% had a history of recurrent depression compared with 10% of non-carriers.

Practical Actions

The circadian delay caused by CRY1Δ11 is mechanistically fixed — the protein is more active than normal — so the goal of treatment is to externally counteract the lengthened period rather than pharmacologically correct it. Two evidence-supported tools phase-advance the circadian clock: morning bright light and evening melatonin.

Morning bright light exposure (10,000 lux for 30 minutes immediately after waking) suppresses residual melatonin and signals the suprachiasmatic nucleus to advance the clock. Evening low-dose melatonin (0.5–3 mg taken 5–7 hours before desired sleep onset) directly phase-advances the melatonin rhythm. Combined bright light plus melatonin produces larger phase shifts than either alone⁹⁹ Combined bright light plus melatonin produces larger phase shifts than either alone
Wilhelmsen-Langeland et al. J Biol Rhythms 2013, PMID 24132057. Because CRY1Δ11 carriers have a genuinely longer intrinsic period, they may need to sustain these interventions indefinitely rather than using them as a one-time correction.

Light avoidance in the evening is equally important. Evening light — especially blue-wavelength light from screens — delays the circadian clock by suppressing melatonin release. For carriers whose clock already runs late, evening light exposure amplifies the misalignment. Blue-light filtering glasses (amber lenses) from roughly 2 hours before desired bedtime reduce this phase-delaying input.

Homozygous carriers (GG) show no more severe clinical phenotype than heterozygous carriers in the published family data, consistent with the dominant gain-of-function mechanism reaching its ceiling with a single copy.

Interactions

CRY1Δ11 operates at the core of the CLOCK:BMAL1 → PER/CRY negative feedback loop. Other clock gene variants that affect this same loop can modulate the overall period length in concert with CRY1Δ11. The CRY2 gene encodes a paralogous cryptochrome; variants in CRY2 associated with earlier chronotype could theoretically counteract some period lengthening, though no published compound analysis exists for the CRY1Δ11 and CRY2 combination in humans.

The rs2287161 variant in CRY1 (a common intronic SNP) has been associated with major depressive disorder and depression risk in multiple populations, and may modulate baseline CRY1 expression levels independently of the CRY1Δ11 splice defect. Carriers of CRY1Δ11 who also carry rs2287161 risk alleles may have a higher burden of mood symptoms than CRY1Δ11 alone predicts.

The PERIOD genes PER1, PER2, and PER3 interact directly with CRY1 protein in the feedback loop. Common variants in PER3 (particularly the VNTR polymorphism rs57875989) affect sleep architecture and circadian preferences independently; their interaction with CRY1Δ11 has not been systematically studied but represents a plausible compounding pathway.

Your blood vessels are not static pipes. They are living structures continuously reshaped by molecular signals — and one of the most important of those signals in the vascular system is BMP9¹¹ BMP9
BMP9 (bone morphogenetic protein 9) is a secreted ligand of the TGF-beta superfamily. Despite the name, it is primarily active in vascular biology, not bone — it is the physiological ligand for the endothelial receptor ALK1 and its co-receptor endoglin. The GDF2 gene encodes BMP9, and the p.Arg68Leu variant — a single amino acid substitution in the prodomain of the protein — disrupts BMP9's ability to mature into its active form, impairs signaling through the ALK1 pathway, and has been linked to a rare vascular malformation syndrome now classified as hereditary hemorrhagic telangiectasia type 5 (HHT5).

HHT is an autosomal dominant disorder affecting an estimated 1 in 5,000 people globally. It is characterized by abnormal blood vessel formations — telangiectases (tiny dilated vessels visible on skin and mucous membranes) and arteriovenous malformations (AVMs) in internal organs including the lungs, liver, and brain. Recurrent nosebleeds (epistaxis) are almost universally the first symptom. GDF2 variants account for a small fraction of HHT cases, and the clinical phenotype of HHT5 overlaps with but differs from the more common HHT1 (ENG) and HHT2 (ACVRL1) forms in ways that have clinical management implications.

The Mechanism

BMP9 is secreted as a large precursor — a prodomain²² prodomain
The prodomain is a regulatory segment that must be cleaved off to release the active mature ligand. For BMP9, the prodomain and the mature domain remain non-covalently associated after cleavage, forming what is called a 'procomplex' attached to a mature signaling domain. Cleavage by furin-family proteases releases the active mature BMP9 dimer, which then binds to ALK1 and its co-receptors (endoglin, BMPR2) on endothelial cell surfaces.

The Arg68 residue sits within the prodomain. In vitro expression studies of the p.Arg68Leu mutant showed that the precursor protein is expressed normally but fails to produce mature BMP9 dimer efficiently³³ fails to produce mature BMP9 dimer efficiently
Processing to mature BMP9 was far less efficient for p.Arg68Leu than wild-type protein; in ALK1 signaling assays the variant showed approximately 79% of wild-type activity at 10 pg/ml and 79% at 30 pg/ml equivalent dilutions — a modest but consistent and reproducible reduction. The biological consequence is reduced BMP9/ALK1/SMAD1/5/8 signaling in endothelial cells, which normally suppresses pathological angiogenesis and maintains AV differentiation. Loss of this brake promotes disorganized vascular sprouting, telangiectasia formation, and AV fistula development.

The Evidence

The p.Arg68Leu variant was identified by Wooderchak-Donahue et al. (2013)⁴⁴ Wooderchak-Donahue et al. (2013)
Wooderchak-Donahue WL et al. Am J Hum Genet 2013 93:530-7 — sequenced 191 patients with suspected HHT who were negative for ENG, ACVRL1, and SMAD4; identified three pathogenic GDF2 missense variants including Arg68Leu in a proband who met clinical HHT criteria (epistaxis and cutaneous telangiectases). The variant co-segregated with disease in family members: the proband's father and sister both carried p.Arg68Leu and reported epistaxis. Functional assays in C2C12 and ATDC5 cells transfected with ALK1 confirmed reduced BMP9 signaling. This variant was absent from 5,400 control exomes, 1000 Genomes, and dbSNP at time of publication, consistent with a rare pathogenic allele under negative selection.

The variant has since been documented in subsequent case literature. A 2025 pediatric HHT cohort study at CHOP identified the p.Arg68Leu variant in one patient (patient 6 in that series), who presented with epistaxis and mucocutaneous telangiectases; the patient's father, carrying the same variant, also had epistaxis — confirming the family segregation pattern originally described.

ClinVar (VCV000088651) classifies the G>T transversion (p.Arg68Leu) as "Likely Pathogenic" for HHT5, based on functional evidence of altered GDF2 protein processing and the clinical presentation of the carrier and affected family members. A second variant at the same codon — p.Arg68His (G>A, ClinVar VCV000646500) — is classified as "Uncertain Significance," highlighting that not every amino acid change at position 68 has the same functional impact.

Separate work has reinforced the dose-sensitivity of BMP9 signaling. Chomette et al. (2023)⁵⁵ Chomette et al. (2023)
Chomette L et al. Am J Med Genet A 2023 191:2157-2167 — described a child with homozygous GDF2 missense at the cleavage site who had both PAH and HHT features; heterozygous parents were entirely asymptomatic, illustrating how homozygous loss of BMP9 is far more severe than haploinsufficiency showed that BMP9 processing mutations can cause pediatric PAH. Heterozygous parents of the affected child remained asymptomatic, consistent with variable expressivity in GDF2-HHT5 generally.

Practical Actions

HHT5 is actionable: vascular screening detects AVMs before they become symptomatic emergencies. Pulmonary AVMs can cause paradoxical emboli (stroke) and hemoptysis. Brain AVMs risk hemorrhagic stroke. Hepatic AVMs cause high-output heart failure in advanced disease. Screening protocols adapted from HHT1/HHT2 guidelines are applied to GDF2 carriers.

The phenotype of GDF2-HHT5 may be milder and less penetrant than HHT1/HHT2 — some carriers have only epistaxis with no solid organ AVMs. Nonetheless, clinical evaluation and baseline screening are warranted in all confirmed or suspected carriers, as visceral AVMs are present in a meaningful proportion of published cases and can be clinically silent until they cause an acute event.

Genetic counseling is essential: HHT5 is autosomal dominant, meaning each first-degree relative of a carrier has a 50% chance of inheriting the variant. The variable expressivity means a parent with only mild epistaxis can have a child with pulmonary AVMs.

Interactions

GDF2 (BMP9) signals through the same endothelial receptor complex as ENG (HHT1) and ACVRL1/ALK1 (HHT2). Variants in ENG and ACVRL1 that reduce receptor availability or signaling would be expected to compound with GDF2 loss-of-function, though digenic HHT from GDF2 plus ENG/ACVRL1 has not been formally documented in published case series. Similarly, SMAD4 loss-of-function (HHT-juvenile polyposis overlap syndrome) disrupts the downstream effector of the same pathway.

BMPR2 is the type II receptor for BMP9, and pathogenic BMPR2 variants are the most common cause of hereditary pulmonary arterial hypertension (hPAH). GDF2 variants can cause both HHT5 and PAH through reduced BMP9/ALK1 signaling, suggesting that concurrent BMPR2 variants might amplify PAH risk in GDF2 carriers, though this interaction has not been systematically studied.

FOXO3 is the most replicated human longevity gene, with protective variants confirmed across European, Asian, and African populations. While the well-characterized rs2802292 G-allele (the HSF1-binding enhancer variant) has been studied primarily in Western and Japanese-American cohorts, rs2253310 captures a distinct signal that may be especially informative for East Asian populations: here, the longevity-protective C allele is the minority allele (~27% in Japanese), while the less-favorable G allele predominates (~73%). This reversed frequency pattern makes rs2253310 a particularly useful genetic marker for East Asian longevity research.

A 2022 longitudinal study¹¹ A 2022 longitudinal study
Ji JS, Liu L, Yan LL, Zeng Y. Comparing Effects of FOXO3 and Residing in Urban Areas on Longevity: A Gene-Environment Interaction Study. J Gerontol A Biol Sci Med Sci. 2022 followed 3,085 Chinese older adults and found CC homozygotes had a 19% lower mortality hazard compared to GG homozygotes (HR 0.808, 95% CI 0.667–0.978), a magnitude comparable to the survival benefit of urban versus rural residence in the same cohort.

The Mechanism

rs2253310 sits in intron 2 of FOXO3 at chromosomal position 108,567,389 (GRCh38, chromosome 6). The gene is on the plus strand, so no strand-complementing is needed — genome files report the same alleles used in publications. The variant does not alter FOXO3 protein sequence; instead, it acts as an [expression quantitative trait locus (eQTL) | a variant that affects how much of a gene product is made, without changing the protein structure], influencing FOXO3 transcription.

A meta-analysis of four longevity cohorts²² A meta-analysis of four longevity cohorts
Bae H, Gurinovich A, Malovini A, et al. Effects of FOXO3 Polymorphisms on Survival to Extreme Longevity in Four Centenarian Studies. J Gerontol A Biol Sci Med Sci. 2018 found that among all 17 tested FOXO3 variants, rs2253310 and rs6911407 showed the most significant effects on FOXO3 expression in brain tissue — a key finding given FOXO3's role in neuronal stress resistance, autophagy, and protection against age-related neurodegeneration.

The rs2253310 G allele's adverse biological direction was confirmed by a 2025 Russian study (n=1,365) showing GG homozygotes face nearly double the risk of chronic obstructive pulmonary disease (OR 1.99, p = 5.93×10⁻⁷) , consistent with lower FOXO3-mediated antioxidant defense in lung tissue of G-allele carriers.

The Evidence

Three independent Chinese longitudinal cohort studies using the Chinese Longitudinal Healthy Longevity Survey demonstrate consistent protective effects of the rs2253310 C allele:

Liu et al. 2021³³ Liu et al. 2021
Liu L, Zhu A, Shu C, Zeng Y, Ji JS. Gene-Environment Interaction of FOXO and Residential Greenness on Mortality Among Older Adults. Rejuvenation Res. 2021 studied 3,179 adults aged 65 and older, finding CC homozygotes had an HR of 0.803 (95% CI 0.666–0.968) for all-cause mortality. Notably, the protective effect of residential greenness was amplified in C-allele carriers, suggesting gene-environment synergy in FOXO3 activation.

Ji et al. 2022 cognitive study⁴⁴ Ji et al. 2022 cognitive study
Ji JS, Liu L, Zeng Y, Yan LL. Effect of FOXO3 and Air Pollution on Cognitive Function. J Gerontol A Biol Sci Med Sci. 2022 tracked cognitive function over 14 years and found C-allele homozygotes had higher baseline MMSE scores and lower odds of cognitive impairment over time. The cognitive protection was strongest in women, older adults, and those in lower air-pollution environments, suggesting that the C allele's FOXO3 expression boost matters most when cellular stress is high.

The blood pressure findings from Morris et al. 2016 add a cardiovascular dimension: among 843 Japanese Americans, women carrying two C alleles had 6 mmHg lower systolic and 3 mmHg lower diastolic blood pressure than GG homozygotes, with essential hypertension prevalence of 3.3% vs 9.5% (P = 0.03–0.04). This gender specificity echoes the pattern seen with other FOXO3 longevity variants, where protective effects are often stronger in women.

Practical Implications

The practical takeaways from rs2253310 mirror those of other FOXO3 longevity variants — all of them point toward the same lifestyle levers for activating FOXO3 expression: fasting, exercise, and stress management. The unique contribution of rs2253310 is its cognitive aging signal: the C allele's strongest effects appear in brain tissue eQTLs, suggesting that brain health across the lifespan may be particularly relevant to this variant.

For GG homozygotes — especially prevalent in East Asian populations — the cognitive aging data suggest that interventions targeting neurological resilience deserve particular emphasis: regular aerobic exercise (which strongly activates FOXO3 in neural tissue), sleep optimization (FOXO3 expression cycles with circadian rhythms), and minimizing chronic oxidative stressors such as air pollution exposure and smoking.

Interactions

rs2253310 lies in the same FOXO3 intron 2 region as rs2802292 and is in high linkage disequilibrium with the broader FOXO3 longevity haplotype. In East Asian populations, the LD pattern differs from European cohorts — rs2253310's C allele is uncommon where rs2802292's G allele may be more common, meaning the two variants may be partially independent signals in Asian ancestries, which could explain rs2253310's distinct detection in Chinese cohort studies rather than primarily in European studies.

The gene-environment interactions documented for rs2253310 — with residential greenness, urban living, and air pollution — are not replicated for most other FOXO3 variants, suggesting this particular intronic position may regulate FOXO3 expression in response to environmental oxidative stress in a way that differs mechanistically from the HSF1-dependent rs2802292 enhancer.

ABCA1¹¹ ATP-Binding Cassette Transporter A1 — a large cell-membrane protein that pumps cholesterol and phospholipids out of cells onto lipid-poor apolipoprotein A-I, the initiating step for HDL particle assembly is the rate-limiting controller of reverse cholesterol transport²² reverse cholesterol transport
the pathway by which excess cholesterol is ferried from peripheral tissues back to the liver for recycling or excretion. When ABCA1 works well, cells shed cholesterol efficiently, nascent HDL forms rapidly, and cardiovascular risk declines. rs2575876 is a common intronic variant in the ABCA1 gene on chromosome 9 that modulates this process in a dose-dependent way — but its most clinically significant effect emerges primarily when both copies carry the A allele.

The Mechanism

rs2575876 sits within an intron of ABCA1 at GRCh38 position 104,903,458. The ABCA1 gene transcribes from the minus strand, so the alleles reported by genome sequencing files (plus strand) are G (reference) and A (alternate). This is a non-coding variant with no direct amino acid change. Its location within the intron places it in a region rich in regulatory elements that have been shown to fine-tune ABCA1 transcription in hepatocytes and other tissues.

The neighboring variant rs2575875³³ rs2575875
a closely related intronic SNP in LD with rs2575876 and rs4149268 in this ABCA1 locus, studied by Howard et al.⁴⁴ Howard et al.
Howard et al. Allele-specific enhancers mediate associations between LCAT and ABCA1 polymorphisms and HDL metabolism. PLOS One, 2019, sits in a transcriptional enhancer that creates an allele-specific STAT3⁵⁵ Signal Transducer and Activator of Transcription 3 — a transcription factor activated by cytokines that loops from intronic enhancers to the ABCA1 promoter, driving hepatic expression binding site. These regulatory variants in tight LD form a haplotype block in which the cumulative effect of homozygosity matters more than any single base change. AA homozygotes at rs2575876 sit at the weaker end of this regulatory spectrum.

The Evidence

The strongest direct evidence comes from a cohort study by Lin et al.⁶⁶ Lin et al.
Lin et al. Association between high-density lipoprotein and functional outcome of ischemic stroke patients in a Taiwanese population. Lipids Health Dis, 2024 of 1,310 first-ever acute ischemic stroke patients. Among two ABCA1 SNPs tested, rs2575876 and rs1883025 were the only two significantly associated with HDL-C levels in the total population and in sex-stratified subgroups. Under a recessive model — AA versus GG+GA combined — rs2575876 AA homozygotes showed measurably different HDL-C levels and a significantly elevated risk of poor functional outcomes at 1 and 3 months post-stroke, particularly when HDL-C was simultaneously abnormal (too low or too high). This recessive pattern implies that a single A allele is largely compensated by the G allele, but two A alleles expose the full effect of reduced ABCA1 regulatory activity.

Genome-wide association data add breadth: multiple large GWAS including the Global Lipids Genetics Consortium (>1.65 million individuals) have identified the ABCA1 locus on chromosome 9 as genome-wide significant for triglycerides and LDL-C, with rs2575876 named as one of the contributing tag SNPs for both traits. Effect sizes are modest — typical of common intronic regulatory variants — but consistent across diverse ancestries.

A broader review by Frikke-Schmidt⁷⁷ Frikke-Schmidt
Frikke-Schmidt R. Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease. Atherosclerosis, 2010 underscores an important nuance: while ABCA1 variants lower HDL-C, genetically low HDL per se does not straightforwardly predict ischemic heart disease risk. The ABCA1-IHD association appears to be partially independent of HDL levels, suggesting ABCA1 has cardioprotective roles beyond cholesterol efflux capacity alone.

Practical Actions

Because the AA genotype is present in only about 5–6% of the population globally, most people carry at least one G allele and will not face the full recessive effect. For AA homozygotes, the priority is monitoring HDL-C and addressing any confirmed deficit through strategies known to improve ABCA1-driven cholesterol efflux: reducing trans fat intake (trans fats directly suppress ABCA1 expression), substituting monounsaturated and omega-3 fats, and sustaining aerobic exercise. If HDL remains below target despite lifestyle efforts, niacin-based options can raise HDL substantially.

The stroke interaction finding signals that when HDL-C goes outside the normal range in AA carriers, recovery from vascular events is compromised. Maintaining HDL-C within normal bounds is therefore especially important for this genotype.

Interactions

The two ABCA1 SNPs most co-studied with rs2575876 are rs1883025 (a nearby variant on the same haplotype block) and rs4149268 (an upstream intronic variant in the same regulatory region). All three tag overlapping ABCA1 regulatory signals; carrying risk alleles across multiple ABCA1 loci may have an additive dampening effect on ABCA1 expression and HDL biogenesis. The R219K missense variant rs2230806 acts through a different mechanism — reducing efflux protein function rather than expression — and may compound the effect of intronic risk alleles. Any ABCA1 variant in combination with APOE ε4 represents a convergent challenge to brain cholesterol homeostasis, given ABCA1's role in neuronal cholesterol efflux.

One of the most studied regions in Crohn's disease genetics sits on chromosome 5q31 — a 250-kilobase stretch called the IBD5 locus¹¹ IBD5 locus
IBD5 was the fifth inflammatory bowel disease susceptibility locus identified by genome-wide linkage analysis; multiple studies from 2001–2006 refined its boundaries and candidate genes. Within this locus, two functional variants in adjacent carnitine transporter genes form a two-allele haplotype that raises Crohn's disease risk by two- to fivefold. rs2631367 is one of those two variants: a single nucleotide change in the promoter of SLC22A5 (encoding OCTN2) that reduces how much carnitine transporter the intestine makes — with significant consequences for mucosal immune homeostasis.

The Mechanism

SLC22A5 encodes OCTN2, a high-affinity sodium-dependent carnitine transporter²² high-affinity sodium-dependent carnitine transporter
Carnitine is an amino acid derivative essential for shuttling long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation; without adequate OCTN2 activity, cells cannot efficiently import carnitine from the circulation expressed prominently in intestinal epithelium, heart, liver, and skeletal muscle. At position -207 in the SLC22A5 promoter, the G allele creates a heat shock element³³ heat shock element
HSEs are short DNA sequences recognized by heat shock transcription factors (HSFs); HSF binding increases gene transcription, especially under stress conditions binding site for heat shock transcription factors. The C allele disrupts this binding site, reducing OCTN2 transcriptional activity. Luciferase reporter assays and lymphoblastoid cell line studies confirmed that haplotypes carrying the -207G allele produce higher OCTN2 mRNA than haplotypes carrying -207C.

In the intestine, this matters beyond fatty acid metabolism. OCTN2-deficient mice⁴⁴ OCTN2-deficient mice
A neonatal mouse model with homozygous OCTN2 deletion showing early intestinal inflammation develop villous atrophy, early lymphocytic and macrophage infiltration, spleen and thymus atrophy via apoptosis, and a pro-inflammatory cytokine profile — a gut and immune phenotype that shares features with Crohn's disease histology. During active inflammatory bowel disease, OCTN2 expression in the terminal ileum is decreased further, suggesting a vicious cycle where inflammation suppresses the transporter and reduced transporter activity fails to protect the epithelial barrier.

rs2631367 forms the promoter component of the IBD5 TC haplotype⁵⁵ TC haplotype
TC stands for the two risk alleles: T at position +1672 in SLC22A4 (OCTN1, rs1050152) and C at position -207 in SLC22A5 (OCTN2, rs2631367); the haplotype was named for the two alleles present simultaneously alongside rs1050152 (L503F in the related OCTN1 transporter). Individually each variant reduces transporter function; together they appear to act additively on intestinal carnitine handling and mucosal barrier integrity.

The Evidence

The landmark study identifying the TC haplotype was published by Peltekova et al. in Nature Genetics⁶⁶ Peltekova et al. in Nature Genetics
Peltekova VD et al., 2004, 36:471–475. They showed that individuals heterozygous for the TC haplotype had odds ratios of 2.1–2.56 for Crohn's disease, while those homozygous for TC/TC had odds ratios of 3.43–5.14 — among the strongest common variant effects reported for IBD at the time. The association was independent of CARD15 variants (the IBD16 locus), and combined TC homozygosity with CARD15 mutations further amplified risk.

Waller et al. (Gut, 2006)⁷⁷ Waller et al. (Gut, 2006)
Waller S et al., 55(6):809–814 confirmed in 1,104 IBD patients and 750 controls that rs2631367 CC genotype carried OR 1.69 (95% CI 1.29–2.22) versus GG, and that the association extended beyond Crohn's disease to ulcerative colitis with comparable effect sizes (P = 0.0001 for overall IBD). The C allele frequency was 52.5% in IBD cases versus 46.3% in controls.

The functional basis of rs2631367 was confirmed by Tahara et al. (J Pharmacol Exp Ther, 2009)⁸⁸ Tahara et al. (J Pharmacol Exp Ther, 2009)
Tahara H et al., 329(1):262–271, who demonstrated that the -207G allele increases OCTN2 transcriptional activity through a heat shock element, while the -207C allele lacks this enhancing element. The functional consequence of lower OCTN2 expression directly reduces intestinal carnitine uptake capacity.

Noble et al. (Gastroenterology, 2005)⁹⁹ Noble et al. (Gastroenterology, 2005)
Noble CL et al., 129(5):1516–1523 extended the analysis to show that OCTN TC haplotype carriers not only had increased Crohn's disease susceptibility but also greater disease severity — homozygous TC/TC carriers were more likely to require intestinal surgery than TC/non-TC patients, suggesting a gene-dosage effect on clinical course.

One important caveat: the entire IBD5 locus is in high linkage disequilibrium¹⁰¹⁰ linkage disequilibrium
LD describes the tendency for nearby variants on the same chromosome to be inherited together more often than random chance; high LD makes it difficult to determine which variant in a region is the true functional cause, and the question of whether the TC haplotype SNPs are causal or merely tagging unknown causal variants remains scientifically debated. The functional data for -207C>G directly affecting OCTN2 transcription strengthens the causal argument considerably.

Practical Implications

For CC homozygotes (highest risk): the evidence supports optimizing carnitine status through dietary sources and monitoring. Red meat and dairy are the richest dietary carnitine sources; individuals with lower OCTN2 expression may benefit from increased intake of carnitine-rich foods. Given the mucosal barrier implications, maintaining intestinal epithelial health through butyrate-producing dietary fiber is also specifically relevant to OCTN2-mediated intestinal dysfunction. Gastrointestinal symptoms — particularly right lower quadrant abdominal pain, changes in stool frequency, bloody stools, or unexplained weight loss — warrant prompt investigation in CC carriers.

For CG heterozygotes: the intermediate risk elevation (approximately 45% increased OR vs GG) is moderate but clinically notable. Awareness of Crohn's disease early symptoms and family history discussion is appropriate.

Interactions

rs2631367 functions as one half of the IBD5 TC haplotype. Its partner, rs1050152 (SLC22A4 L503F, T allele), is an independent OCTN1 missense variant that alters ergothioneine transport. The combined TC genotype at both loci produces the full IBD5 risk signal; carriers of the C allele at rs2631367 without the T allele at rs1050152 may have somewhat reduced risk compared to TC haplotype homozygotes.

The IBD5 locus interacts with the CARD15/NOD2 locus (chromosome 16): Peltekova et al. showed that TC haplotype homozygosity combined with CARD15 mutations substantially elevated Crohn's disease risk beyond either alone, consistent with independent pathway effects (bacterial sensing via NOD2 + intestinal barrier via OCTN2).

Every time you climb stairs, sprint for a bus, or carry groceries, your muscle cells burn through their internal glycogen stores in the first few seconds of exertion. The enzyme responsible for unlocking those stores is myophosphorylase¹¹ myophosphorylase
muscle-specific glycogen phosphorylase, encoded by PYGM on chromosome 11q13 — and in McArdle disease, it doesn't work. Glycogen accumulates unused inside muscle fibers while the cells starve for the glucose they need.

The rs267606993 variant (c.1A>G, p.Met1Val) eliminates the start codon of PYGM entirely. The coding sequence begins with ATG — methionine — and the A>G substitution on the coding strand converts that to GTG (valine). In theory this creates a missense change, but in practice the next available in-frame methionine is at codon 92, meaning any protein produced from the alternate start site is severely truncated and non-functional. The gene effectively produces nothing useful. ClinVar classifies this variant²² ClinVar classifies this variant
ClinVar VCV000002309, pathogenic, multiple submitters no conflicts as pathogenic for glycogen storage disease type V (GSD-V, McArdle disease).

The Mechanism

In healthy muscle, glycogen phosphorylase cleaves glucose-1-phosphate from glycogen chains at the start of exercise, feeding glycolysis to produce ATP. This process is especially critical in the first 8–10 minutes of sustained exertion, before fatty acid oxidation and increased cardiac output can meet energy demand. Without myophosphorylase, muscle cells cannot access their glycogen reserve at all. They rely entirely on blood glucose and fatty acids from the start of exercise — supplies that arrive too slowly in early exertion, producing the characteristic cramping and weakness of McArdle disease.

The "second wind" phenomenon — one of the most distinctive features of McArdle disease — reflects this metabolic bottleneck: after 8–10 minutes of moderate activity, blood glucose delivery, fat mobilization, and heart rate adaptation catch up, and exercise becomes much more tolerable. Patients who learn to pace themselves through the initial difficulty often exercise reasonably well once the second wind arrives.

The Evidence

The Met1Val variant was first identified by Vorgerd et al.³³ Vorgerd et al.
Vorgerd M et al. Mutation analysis in myophosphorylase deficiency (McArdle's disease). Ann Neurol, 1998 in a homozygous Turkish patient. The same research confirmed that R50X (p.Arg50*) is the dominant PYGM mutation in European white populations (allelic frequency ~60%), while start-codon and other loss-of-function variants account for a smaller but well-documented share of cases.

A larger European cohort study by Vieitez et al.⁴⁴ Vieitez et al.
Vieitez I et al. Molecular and clinical study of McArdle's disease in a cohort of 123 European patients. Neuromuscul Disord, 2011 identified 20 novel PYGM mutations across 123 patients and found no genotype-phenotype correlation — the specific PYGM mutation carried does not predict disease severity. This means a patient with Met1Val can have mild or severe disease independent of which variant they carry.

The Met1Val variant emerged as the most prevalent PYGM mutation in Turkish patients in a study by Inal-Gültekin et al.⁵⁵ Inal-Gültekin et al.
Inal-Gültekin G et al. Myophosphorylase (PYGM) mutations determined by next generation sequencing in a cohort from Turkey with McArdle disease. Neuromuscul Disord, 2017, found in 27 of 67 patients across 11 families, illustrating the population-specific distribution of PYGM alleles.

McArdle disease affects approximately 1 in 100,000–170,000 people globally. Life expectancy is normal, though about 11% of patients develop permanent proximal weakness after age 40 and half experience episodes of myoglobinuria that can threaten kidney function if severe.

Practical Actions

The key interventions for McArdle disease are specific to myophosphorylase deficiency and would not be recommended to anyone without a genetic test:

Pre-exercise sucrose: Consuming 25–40 g of sucrose (a glass of orange juice, a banana, or a sports drink) 5 minutes before exercise significantly improves exercise tolerance by elevating blood glucose before myophosphorylase is needed. This is the single most validated pharmacological/nutritional intervention in McArdle disease, specific to the metabolic block.

The warm-up strategy: Starting exercise at very low intensity for 10 minutes allows the second wind to arrive before high-intensity effort begins. Patients trained in this strategy show dramatically reduced exercise-related cramps and myoglobinuria risk compared to sudden high-intensity bursts.

Myoglobinuria recognition: Dark, cola-colored urine after exercise signals rhabdomyolysis — acute muscle breakdown releasing myoglobin, which is filtered by the kidneys. Any episode requires immediate rest, high fluid intake, and medical evaluation; severe episodes cause acute kidney injury.

Regular aerobic exercise: Supervised aerobic training (starting at 30% of VO2max, increasing gradually) improves mitochondrial capacity and thus reduces dependence on early glycogenolysis. This is a genotype-specific rationale for structured aerobic conditioning that would not be recommended to unaffected individuals.

Interactions

This is an autosomal recessive variant. Compound heterozygosity — inheriting Met1Val on one chromosome and a different pathogenic PYGM variant (such as R50X, Gly205Ser, or any of the ~180 known pathogenic alleles) on the other — produces full McArdle disease phenotype equivalent to homozygosity. The diagnostic implication for carriers is primarily reproductive: if both parents carry any pathogenic PYGM variant, each child has a 25% chance of inheriting biallelic loss-of-function alleles and developing GSD-V.

Note on multi-allelic representation: rs267606993 is a multi-allelic site at the PYGM start codon with three pathogenic alternate alleles on the plus strand (T>A = p.Met1Leu; T>C = p.Met1Val; T>G = p.Met1Leu via different codon). This entry represents the T>C (Met1Val) variant as the primary risk allele (C), consistent with ClinVar VCV000002309. The other two alternates (ClinVar 553271, 156341) have identical clinical significance and are captured under the same rsID.

The GABRA2 gene encodes the alpha-2 subunit of the GABA-A receptor, the brain's primary inhibitory neurotransmitter system.

The alpha-2 subunit participates in transporting chloride ions into neurons, causing hyperpolarization and inhibitory effects .

This subunit is found primarily in the hippocampus and forebrain , and

GABA-A receptors can be modulated by benzodiazepines and other agents that bind to the receptor .

Rs279858 is a synonymous SNP in exon 5 of GABRA2 , meaning it doesn't change the amino acid sequence¹¹ it doesn't change the amino acid sequence
This is called a silent mutation - the DNA changes from T to C, but the protein remains unchanged because both codons specify lysine (K132K).

This variant lies within a 140 kb haplotype block that has been reproducibly associated with alcohol dependence across multiple populations .

The Mechanism

Although rs279858 is synonymous, it has functional consequences²² it has functional consequences
Synonymous variants can affect gene expression through multiple mechanisms: mRNA stability, splicing, translation efficiency, and linkage to regulatory variants.

Research using induced pluripotent stem cells found significantly lower levels of GABRA2 mRNA in neural cell cultures derived from C-allele carriers .

C-allele carriers show a low-expression cluster pattern for all four chromosome 4p12 GABA-A genes , suggesting the variant or linked variants affect expression of the entire gene cluster³³ the variant or linked variants affect expression of the entire gene cluster
The chromosome 4p12 cluster includes GABRG1, GABRA2, GABRA4, and GABRB1.

Reduced GABRA2 expression in the temporal and prefrontal cortex has been linked to higher anxiety levels in rodents . The reduced inhibitory signaling may explain why C-allele carriers experience altered subjective responses to alcohol⁴⁴ altered subjective responses to alcohol
The "high" and stimulation from alcohol and increased anxiety-related traits⁵⁵ increased anxiety-related traits
Including nervous feelings and reduced risk-taking behavior.

The Evidence

Alcohol dependence:

Variants in this haplotype block have been replicated in multiple studies across different populations .

A meta-analysis combining multiple datasets found P=5×10⁻⁶ (OR=1.18) for association with alcohol dependence in Europeans .

In a validation study of 1,032 heroin users and 2,863 controls, the G-allele frequency was significantly higher in substance users (p<0.001, OR=0.84) .

The direction of effect varies by context.

One study found that C-allele carriers reported greater feelings of "high" and liking alcohol's effects . However, among already-dependent drinkers, T-allele homozygotes showed greater stimulation, suggesting the influence differs by stage of dependence .

Higher recent drinking was associated with reduced acute tolerance in risk allele carriers .

Anxiety and behavioral traits:

A phenome-wide association study found the C-allele associated with anxiety-related phenotypes, including reduced risk-taking behavior, increased nervous feelings, and reduced number of lifetime sexual partners .

These traits may be related to anxiety or behavioral inhibition identified as a risk factor for alcohol use disorders .

Neurocircuitry:

The G-allele was associated with heightened nucleus accumbens activation during adolescence , a critical period for addiction vulnerability.

In healthy controls, G-allele carriers showed significantly decreased reward network connectivity compared to A-allele carriers .

Aggression:

In patients with alcohol dependence, carriers of a specific A-C haplotype (rs567926-rs279858) were more likely to demonstrate aggressive behavior , and this rare haplotype (1.6%) was more frequent in Cloninger's type II alcoholism , characterized by early onset and aggression.

Practical Implications

This variant influences how you experience alcohol and your vulnerability to developing problematic drinking patterns. The C-allele is associated with enhanced subjective effects of alcohol — feeling more "high," stimulated, and euphoric from drinking. This heightened response can paradoxically increase risk for alcohol dependence, as the rewarding effects may drive continued use⁶⁶ the rewarding effects may drive continued use
This is called incentive-sensitization theory of addiction.

The C-allele also predisposes to anxiety-related traits.

Reduced GABRA2 expression has been linked to higher anxiety in animal models, and anxiolytic drugs increase GABRA2 expression . If you carry one or two C-alleles, you may benefit from non-pharmacological anxiety management strategies⁷⁷ non-pharmacological anxiety management strategies
These work through multiple mechanisms including HPA axis regulation and neuroplasticity like regular exercise, mindfulness practices, and adequate magnesium intake⁸⁸ adequate magnesium intake
Magnesium acts as a natural GABA-A receptor modulator.

For those with the CC or CT genotype and a family history of alcohol problems, awareness of enhanced alcohol sensitivity is protective. Studies show that education about genetic risk can motivate harm-reduction behaviors⁹⁹ Studies show that education about genetic risk can motivate harm-reduction behaviors
This is called personalized prevention.

Interactions

Rs279858 is in strong linkage disequilibrium with other GABRA2 variants including rs567926, rs279826, and rs279871. These variants form two major haplotypes that differ in addiction risk. Additionally, the chromosome 4p12 region contains a cluster of related GABA-A receptor genes (GABRG1, GABRA2, GABRA4, GABRB1) whose expression appears coordinated. Variants affecting this entire cluster may have compounded effects on GABAergic neurotransmission.

Environmental factors strongly moderate genetic effects. Studies show that GABRA2 variants interact with parental monitoring, peer deviance, and stressful life events to influence externalizing behavior and substance use. The genetic vulnerability is expressed primarily in high-risk environments, consistent with a diathesis-stress model.

Deep beneath the skin, an invisible infrastructure of lymphatic vessels works alongside your veins to return fluid to circulation. The gene PROX1 — prospero homeobox 1¹¹ prospero homeobox 1
a transcription factor named for the Drosophila gene prospero, which controls cell identity — is the master regulator of lymphatic endothelial cell identity. Without PROX1, lymphatic vessels fail to form correctly; without properly formed lymphatic vessels and their valves, venous pressure rises and varicose veins develop. The rs340875 variant lies within an intron of PROX1, likely influencing how much of this transcription factor is produced in the endothelial cells that line lymphatic and venous valves.

The Mechanism

PROX1 sits at the apex of a transcriptional cascade that determines whether an endothelial progenitor cell becomes a lymphatic endothelial cell (LEC) rather than a blood vascular cell. It does this by forming a complex with β-catenin and TCF7L1²² forming a complex with β-catenin and TCF7L1
components of the Wnt signaling pathway, which translates mechanical and biochemical cues into gene expression changes to amplify expression of two subordinate transcription factors, FOXC2 and GATA2, that are essential for the assembly and maintenance of lymphatic valve leaflets.

When PROX1 is deleted from valvular endothelial cells³³ When PROX1 is deleted from valvular endothelial cells
Ho et al. 2023 Circulation Research, the consequence is progressive valve degeneration: aortic and mitral valves become thick and myxomatous, FOXC2 expression falls, and extracellular matrix composition is disrupted with excess proteoglycan accumulation. PROX1 suppresses PDGF-B signaling to maintain healthy valve architecture; without it, PDGF-B runs unchecked and the valve structure breaks down.

rs340875 is an intronic variant — it does not change the PROX1 protein sequence, but intronic variants in transcription factor genes can alter splicing efficiency, mRNA stability, or regulatory element activity, affecting the total amount of functional protein produced in endothelial tissues. The C allele is the risk-associated allele identified at the PROX1 locus in varicose veins genetics.

The Evidence

Ahmed et al. 2022⁴⁴ Ahmed et al. 2022
Genome-wide association analysis and replication in 810,625 individuals with varicose veins, Nature Communications conducted the largest varicose veins GWAS to date: 135,514 cases and 675,111 controls drawn from UK Biobank (401,656 individuals) and the 23andMe research cohort (408,969 individuals). The study identified 49 independent genetic signals across 46 susceptibility loci, mapping 237 genes. Pathway analysis confirmed enrichment in lymphangiogenesis — implicating genes like PROX1 that regulate lymphatic vessel formation and valve integrity.

The PROX1 gene's role in valve disease extends beyond varicose veins. PROX1 is classified as required for the development of both lymphatic and venous valves; its loss from endothelial cells is sufficient to cause progressive myxomatous degeneration⁵⁵ sufficient to cause progressive myxomatous degeneration
myxomatous meaning the valves accumulate abnormal proteoglycan-rich matrix that makes them floppy and incompetent of aortic and mitral valves. High PROX1 expression in specific endothelial cells is also the initiating signal for lymphatic valve specification⁶⁶ initiating signal for lymphatic valve specification
Qu et al. 2015 Developmental Biology; cells that fail to upregulate PROX1 do not enter the valve-forming program.

The evidence level for rs340875 specifically is moderate: the PROX1 locus is robustly identified in a very large GWAS, and the biological mechanism is well-established, but the specific functional effect of rs340875 on PROX1 expression or splicing has not been independently characterized at the molecular level.

Practical Actions

For people carrying one or two C alleles at rs340875, the most directly relevant interventions address the lymphatic-venous drainage impairment that underlies varicose veins and venous insufficiency. Compression therapy is the first-line evidence-based intervention for venous reflux regardless of cause; for carriers of a lymphatic gene variant, it directly compensates for the drainage deficit that PROX1 reduction creates. Elevation reduces hydrostatic pressure in the dependent leg veins. Avoiding prolonged static postures — standing or sitting without movement — is specifically important when lymphatic pump function is genetically compromised.

Interactions

PROX1 operates at the top of the lymphatic transcriptional hierarchy. Its downstream targets include FOXC2 (encoded by FOXC2 at chromosome 16q24.1 — mutations in FOXC2 cause lymphedema- distichiasis syndrome) and GATA2. Variants in FOXC2, GATA2, or other lymphatic valve genes interacting with PROX1 may compound the risk of venous insufficiency in carriers of the rs340875 C allele, although specific gene-gene interaction data for this variant are not yet published.

Among the three independent protein-coding protective variants in TYK2, Ala928Val stands apart for the strength of its individual effect. While rs12720356 (Ile684Ser) confers roughly 14% protection per allele and rs34536443 (Pro1104Ala) roughly 24% per allele, the A928V variant confers an odds ratio of 0.53¹¹ odds ratio of 0.53
OR 0.53 means approximately 47% lower odds of rheumatoid arthritis per allele — one of the strongest individual coding-variant effects documented for any autoimmune disease at this sample scale for RA per allele in the largest fine-mapping study conducted at this locus. It is also the rarest of the three, with a minor allele frequency of approximately 0.8% in Europeans and near-zero frequency in East Asian and African populations.

TYK2²² TYK2
Tyrosine kinase 2, a Janus kinase (JAK) family member that transduces signals from cell-surface receptors for IL-12, IL-23, and type I interferons (IFN-α/β) into intracellular gene expression changes driving T cell activation and inflammatory amplification controls the signaling intensity of three of the most important inflammatory cytokine axes in autoimmune disease. Its pseudokinase (JH2) domain is a regulatory scaffold — a non-catalytic structure that modulates the adjacent kinase (JH1) domain and determines how strongly each cytokine signal is amplified.

The Mechanism

TYK2 mediates downstream signaling for the IL-12 receptor (activating STAT4, driving Th1 differentiation), the IL-23 receptor (activating STAT3/STAT4, driving Th17 responses), and the type I interferon receptors IFNAR1/2 (activating JAK1-STAT1/STAT2, driving antiviral and lupus-relevant responses). The JH2 pseudokinase domain acts both as an autoinhibitory brake on basal activity and as a positive regulator that amplifies signal intensity when cytokine receptors are engaged.

The Ala928Val substitution occurs within the JH2 domain at a position that contributes to the intradomain contacts that maintain the regulatory architecture. Replacing the small, non-polar alanine with the bulkier, branched valine introduces steric constraints that partially disrupt the JH2 domain's ability to positively regulate JH1 catalytic function. The result is a [hypomorphic TYK2 | Hypomorphic means partially reduced function rather than complete abolition — the protein is present and active but with reduced signal amplification capacity] that retains sufficient activity for antiviral and homeostatic signaling but measurably dampens the inflammatory amplification loops most relevant to autoimmune tissue damage.

All three TYK2 missense variants (P1104A, I684S, and A928V) were predicted damaging by both PolyPhen-2 and SIFT³³ predicted damaging by both PolyPhen-2 and SIFT, consistent with their functional impairment of the JH2 domain.

The Evidence

The primary genetic evidence comes from Diogo et al. (2015)⁴⁴ Diogo et al. (2015), who combined dense Immunochip genotyping (23,092 RA case/control samples), Exomechip genotyping (18,409 subjects), and targeted exon sequencing (2,236 samples). Conditional analysis and haplotype analysis confirmed that P1104A, I684S, and A928V each lie on distinct haplotype backgrounds and each contribute an independent signal. The A928V effect (OR 0.53, P=1.2×10⁻⁹) survives conditioning on both other signals, establishing it as a genuine causal variant rather than a tag for its sibling alleles. The same omnibus test combining all three TYK2 variants found joint protection against SLE at P=6×10⁻¹⁸.

The 2021 systematic review and meta-analysis by Pellenz et al.⁵⁵ 2021 systematic review and meta-analysis by Pellenz et al. (34 studies, 8 autoimmune conditions) confirmed rs35018800's protective minor allele association across multiple autoimmune diseases alongside the other four TYK2 protective SNPs.

The biological plausibility of A928V is strengthened by parallel cellular mechanistic work on the TYK2 JH2 variant class. Gorman et al. (2019)⁶⁶ Gorman et al. (2019) showed that JH2-domain impairment specifically limits TYK2 signaling under multi-pathway co-activation — the scenario characteristic of active autoimmune disease — while preserving single-pathway responses needed for infection control. Enerbäck et al. (2018)⁷⁷ Enerbäck et al. (2018) demonstrated directly in human blood that a neighboring JH2 variant (I684S) reduces IL-12- stimulated STAT4 phosphorylation in skin-homing T cells, providing the cellular readout expected from A928V's structurally analogous JH2 impairment.

Notably, unlike TYK2 P1104A (rs34536443), no published study has identified a cancer immune- surveillance trade-off (elevated lung cancer or NHL) associated with the A928V variant. This may reflect the variant's rarity — it is statistically underpowered for cancer-association analysis in existing datasets — but no signal has emerged in the large PheWAS performed by Diogo et al. across more than 500 phenotypes.

Practical Implications

With a European MAF of approximately 0.8%, about 1.6% of Europeans carry at least one A allele at rs35018800 (nearly all heterozygous AG, with AA homozygotes vanishingly rare). The variant is essentially absent in East Asian, South Asian, and African populations, making it primarily a European-ancestry finding in current databases.

The OR 0.53 per allele is among the strongest individual SNP effects documented for common autoimmune diseases. For a heterozygous carrier, this translates to approximately 47% lower odds of RA from this locus alone — comparable in effect size to some drug treatments. This result is relevant in the same clinical contexts as the other TYK2 protective alleles: autoimmune disease workup interpretation, family history counseling for RA and SLE, and biologic therapy discussions. If deucravacitinib or a JAK inhibitor is prescribed, the A928V allele contributes an independent layer of baseline TYK2 JH2 attenuation that the prescriber should be aware of.

Interactions

rs35018800 (A928V) is confirmed by haplotype analysis to reside on a distinct haplotype background from rs34536443 (P1104A, MAF ~4% in Europeans) and rs12720356 (I684S, MAF ~8% in Europeans). An individual who carries protective alleles at more than one of these three loci has multiple independent layers of TYK2 JH2 attenuation — the protections are additive in principle because the structural disruptions occur at different intradomain contacts.

rs2304256 (V362F) in TYK2 operates through a separate mechanism involving exon 8 splicing and FERM domain receptor binding. Its GWAS association signal in SLE and RA has been shown to be largely driven by linkage disequilibrium with the coding variants including I684S, and it is functionally and genetically independent from A928V.

Beyond TYK2, A928V operates within the same autoimmune genetic architecture as rs2476601 (PTPN22 R620W, T cell receptor threshold) and rs3087243 (CTLA4 CT60, costimulation threshold). These variants modulate T cell activation at distinct checkpoints and likely provide additive protection when co-inherited with protective TYK2 alleles, though formal compound heterozygosity studies have not been published.